Researchers at the University of Montreal Health Center have created a prognostic tool that fills an important gap in forecasting early recurrence of disease following radical prostatectomy.
Malpractice Consult: What to know about direct examination of lay witnesses
"To form a connection between the witness and the jury and establish the witness’ credibility, the witness needs to be the star," writes Austin M. Richards, Esq.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Expert highlights cybersecurity regulation updates for health care organizations
There have been several recent regulatory updates related to cybersecurity in health care.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
What the SWIU Census reveals about the state of women in urology
"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.
Phase 2 trial to evaluate NTD inhibitor in metastatic CRPC
Patients with mCRPC will be randomly assigned 2:1 to receive masofaniten/enzalutamide or enzalutamide alone.
2 Clarke Drive Cranbury, NJ 08512